Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Lee P. Resta"'
Autor:
Sabine Ermisch, Ting Wang, Michael A. Carducci, Jeannette Day, Deborah K. Armstrong, Lori Kornberg, Rodney Decker, Connie Collins, Steven J. Nicol, Donald Thornton, Lee P. Resta, Zhe Zhang, Nwabundo Nwankwo
Publikováno v:
Investigational New Drugs
Summary Purpose Given distinct mechanism of actions of enzastaurin and bevacizumab, preclinical studies suggest enhanced antitumor activity in combination. This phase I study assessed the combination’s safety and efficacy. Patients and methods Six
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::472eebf5ca200034f61e7d9df3fcb0b9
https://doi.org/10.1007/s10637-012-9850-6
https://doi.org/10.1007/s10637-012-9850-6
Autor:
Serina King, Avery Spitz, Ramesh Boinpally, Roberto Pili, Mario A. Eisenberger, Amy Franke, Christopher Sweeney, Michael A. Carducci, Jennifer M. Porter, Lee P. Resta
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose To find the maximum tolerated dose (MTD) of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors. Methods This was a Phase I study using cohort dose escalation of OSI-461 dosed orally twice daily in combination with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79f683f7bdcef003a51ff04c5617448d
https://pubmed.ncbi.nlm.nih.gov/20445979
https://pubmed.ncbi.nlm.nih.gov/20445979
Autor:
Resta, Lee, Pili, Roberto, Eisenberger, Mario, Spitz, Avery, King, Serina, Porter, Jennifer, Franke, Amy, Boinpally, Ramesh, Carducci, Michael, Sweeney, Christopher
Publikováno v:
Cancer Chemotherapy & Pharmacology; Feb2011, Vol. 67 Issue 2, p431-438, 8p